CCN1 inhibition increases Imatinib-induced apoptosis of CML cells in vitro and restores the sensitivity of CML cells to Imatinib in vivo (Song et al. 2019). The gene discussed is CCN1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.